UltraGene Assay SARS-CoV-2 Multi Variants Deletions V1 for Screening & Identification of 3 different SARS-CoV-2 Variants is now CE-IVD Marked

ABL is pleased to announce today that the UltraGene Assay SARS-CoV-2 Multi Variants Deletions V1, a direct qPCR assay to be used on already SARS-CoV-2 positive samples (no need to do additional RNA isolation), received CE-IVD Marking.
The kit, targeting 5 different genomic variations on 3 genes in a multiplex format (single well) can be used to screen and identify 3 lineages (possibly associated with an increased infectivity and transmissibility):
  • SARS-CoV-2 lineage B.1.1.7 (i.e. United Kingdom VOC 202012/01, VOC 202102/02; “UK”)
  • SARS-CoV-2 lineage B.1.351 (i.e. South Africa VOC 202012/02; “SA”)
  • SARS-CoV-2 lineage P.1 (i.e. Brazil VOC 202101/02; “BR”)

For more information please contact us at the following email address:

contact@ablsa.com